Matinas biopharma announces collaboration with national resilience to explore and evaluate novel lnc platform delivery technology for certain nucleic acids

Bedminster, n.j., jan. 12, 2023 (globe newswire) -- matinas biopharma (nyse amer: mtnb), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (lnc) platform technology, today announced a strategic collaboration with national resilience, inc. (resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines. the parties have entered into a material transfer and evaluation agreement focused on exploring the potential for oral delivery of identified nucleic acids. the parties will closely collaborate on a comprehensive research program comprising the design, formulation, optimization, and in vitro and in vivo testing of these nucleic acid formats in combination with matinas' proprietary lnc platform. terms of the collaboration were not otherwise disclosed.
MTNB Ratings Summary
MTNB Quant Ranking